• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    BG Medicine, Inc. (BGMD)

    0.33 Down 0.00(1.46%) Dec 19, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    BG Medicine, Inc.
    880 Winter Street
    Suite 210
    Waltham, MA 02451
    United States - Map
    Phone: 781-890-1199
    Fax: 781-895-1119
    Website: http://www.bg-medicine.com

    Index Membership:N/A
    Industry:Medical Laboratories & Research
    Full Time Employees:23

    Business Summary 

    BG Medicine, Inc., a diagnostics company, develops and commercializes novel cardiovascular diagnostic tests to address unmet medical needs in the United States. The company offers BGM Galectin-3 test, a novel assay for measuring galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of patients diagnosed with heart failure; and CardioSCORE test, which is designed to identify individuals at high risk for cardiovascular events, such as heart attack and stroke. It has license, development, and commercialization agreements with Abbott Laboratories, Alere Inc., bioMérieux SA, and Siemens Healthcare Diagnostics Inc. for the development of galectin-3 test on their automated instrument platforms; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on BG Medicine, Inc.

    Corporate Governance 
    BG Medicine, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 7; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Paul R. Sohmer M.D., 65
    Chief Exec. Officer, Pres and Director
    Dr. Noubar B. Afeyan Ph.D., 51
    Founder, Director, Chairman of Compensation Committee and Member of Nominating & Governance Committee
    Dr. Aram Adourian Ph.D., 44
    Chief Scientific Officer and Sr. VP
    Dr. Jan van der Greef Ph.D.,
    Founder and Scientific Advisor of RDAB Board
    Mr. Stephen P. Hall , 63
    Chief Financial Officer, Principal Accounting Officer, Exec. VP and Treasurer
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders